NetworkNewsBreaks

MondayMar 20, 2017 1:34 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 20, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ATLT 20.00% – News: Expects significant gains for Q3 ended March 31, 2017 NMUS 18.37% – News: Signs development agreement with Nanomerics Ltd. for ocular formulation NB1111 AKDS 15.79% – News: Inks LOI to acquire SolBright Renewable Energy GLBR 13.79% – News: Posts Q4 2016 results COYN 8.36% – News:  COPsync Network continues to grow ALQA 8.10% – News: Peer-reviewed study on MIST Therapy for deep tissue pressure injuries published in Wound Repair &…

Continue Reading

MondayMar 20, 2017 12:15 pm

NetworkNewsBreaks – BioLineRx (NASDAQ: BLRX) Reports Interim Results on Phase 2 Study of BL-8040 in Stem Cell Mobilization

BioLineRx (NASDAQ: BLRX) this morning reported partial results data from its open-label phase 2 trial for BL-8040 as a novel monotherapy approach for the mobilization and collection of blood forming stem and progenitor cells from the peripheral blood. Interim results from the initial cohort of donor and recipient pairs show that a single injection of BL-8040 mobilized sufficient amounts of cells required for transplantation at a level of efficacy similar to that achieved by using 4-6 injections of G-CSF, the current standard of care. So far, all transplant recipients have experienced a successful neutrophil engraftment. Recipients will continue to be…

Continue Reading

MondayMar 20, 2017 11:50 am

NetworkNewsBreaks – Cerulean Pharma (NASDAQ: CERU) Shares Dive on Stock Purchase Agreement with Daré Bioscience

Shares of Cerulean Pharma (NASDAQ: CERU) dropped 60% this morning after the company said it entered a definitive stock purchase agreement with Daré Bioscience, Inc. under which the equityholders of Daré will become the majority owners of Cerulean. The transaction will result in a public, Nasdaq-listed company focused on the development and commercialization of products for women’s reproductive health. Daré’s product candidate, Ovaprene®, is a clinical stage, non-hormonal contraceptive ring for monthly use that potentially addresses a significant unmet need in the $16 billion global contraception market. The combined company will operate under the name Daré; its CEO will be…

Continue Reading

MondayMar 20, 2017 11:47 am

NetworkNewsBreaks – FuelCell Energy, Inc. (NASDAQ: FCEL) Attends Dedication of Another Fuel Cell Park by Partner POSCO Energy in Seoul

FuelCell Energy (NASDAQ: FCEL) shares are ticking higher after the company announced the dedication event of the Noeul Green Energy Co. fuel cell park in Seoul, South Korea. The 20 megawatt fuel cell park supplies ultra-clean power to the electric grid and high quality heat to a district heating system and was constructed by the company’s South Korean partner POSCO Energy in just 10 months. Members of FuelCell Energy’s executive management joined POSCO Energy executives, government officials and customers to celebrate the operation of this fuel cell park. “This project exemplifies the benefits of fuel cell installations by locating the…

Continue Reading

MondayMar 20, 2017 11:43 am

NetworkNewsBreaks – Medical Transcription Billing, Corp. (NASDAQ: MTBC) Announces Monthly Dividend on Series A Preferred Stock

Health care information technology company Medical Transcription Billing, Corp. (NASDAQ: MTBC; MTBCP) this morning announced that its board of directors has declared monthly cash dividends for its 11% Series A Cumulative Redeemable Perpetual Preferred Stock for March, April and May of this year. Holders of these shares are entitled to receive cumulative cash dividends at the rate of 11% of the $25 per share liquidation preference per annum, which is equivalent to $2.75 per year per share. The applicable record date related to this dividend will be the last day of the calendar month, with the dividend becoming payable on…

Continue Reading

MondayMar 20, 2017 10:22 am

NetworkNewsBreaks – Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) SAGA Trial Fails to Reach Primary Endpoint; Shares Plummet

Shares of Aevi Genomic Medicine (NASDAQ: GNMX) dropped 60% shortly after market open on news that the company’s AEVI-001 did not meet the primary endpoint of reduction on the ADHD rating scale (ADHD-RS) compared to placebo; however, there was improvement observed on the inattention subscale. The results also show efficacy and benefit to patients in two pre-specified responder analyses: ADHD-RS improvement of 30% or more, which was met by 70% of patients treated with AEVI-001 versus 42% on placebo; and Clinical Global Impression of Improvement scale (CGI-I), resulting in 57% of patients treated with AEVI-001 achieving a score of much…

Continue Reading

MondayMar 20, 2017 10:14 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Establishes XiBiDi Biotechnology Co., Ltd. in Shanghai Free-Trade Zone

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced the establishment and registration of XiBiDi Biotechnology Co., Ltd. in the Shanghai Free-Trade Zone. Moving forward, XiBiDi will focus on the online and offline sales of health products featuring hemp-derived cannabidiol (CBD) oil, in addition to hemp-based food and beverages. Additionally, the new company will serve as operator of CIIX’s recently-launched CBD online store, www.ChineseCBDoil.com. “I am delighted about the establishment and registration of our new hemp company,” Warren Wang, founder and CEO of CIIX, stated in this morning’s news release. “XiBiDi Biotechnology is strategically located in the Pudong Free-Trade…

Continue Reading

FridayMar 17, 2017 12:34 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 17, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: XGTI 16.90% – News: Posts final payment on deferred debt from Vislink acquisition ABUS 14.04% – News: Moving on momentum from recent license agreement NSPXD 12.50% – News: Signs agreement with Milost Global, Inc. for a commitment of up to $100M AVID 5.62% – News: Law firm announces investigation SITO 5.50% – News: Law firm issues reminder for class action lead plaintiff deadline of April 18 GLBR 5.05% – News: Law firm issues reminder…

Continue Reading

FridayMar 17, 2017 12:31 pm

NetworkNewsBreaks – Acura Pharmaceuticals (ACUR) Inks License Agreement with MainPointe Pharmaceuticals for Nexafed® Products

Acura Pharmaceuticals (OTCQB: ACUR) shares are up 5% on news that the company has entered into a License Agreement with MainPointe Pharmaceuticals, LLC in which MainPointe will exclusively market NEXAFED and NEXAFED Sinus in the U.S. and Canada. The NEXAFED brand products, which contain pseudoephedrine, utilize Acura’s IMPEDE® Technology, which disrupts the extraction and conversion of pseudoephedrine into the illicit drug methamphetamine. MainPointe will assume all manufacturing and commercialization activities from Acura. Per the agreement, MainPointe is required to make an upfront cash payment of $2.5 million to Acura, as well as royalty payments of 7.5% based on commercial sales by…

Continue Reading

FridayMar 17, 2017 12:28 pm

NetworkNewsBreaks – BioSig Technologies, Inc. (BSGM) Signs Strategic Agreement with Mayo Clinic

BioSig Technologies (OTCQB: BSGM) shares rose 10% after the company signed a 10-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures. The new agreement expands upon the work realized under the Advanced Clinical Research Program that was signed with Mayo Clinic in March 2016. The company intends to work closely with leading Mayo electrophysiologists Drs. Samuel Asirvatham and K. L. Venkatachalam to develop advanced clinical features and applications for its PURE EP System, in addition to leveraging its experience in physiologic signal processing to develop future technologies. Mayo is expected to contribute knowledge, intellectual property and clinical support to the partnership. The…

Continue Reading